Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of RMC BCMA CART in relapsed or refractory multiple myeloma
MOH_2024-11-03_013658Phase 2Not yet recruiting
- Sponsor
- ד"ר ליאת שרגיאן
- Start
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of RMC BCMA CAR T-cell therapy in multiple myeloma (MM) (2 arms), sponsored by ד"ר ליאת שרגיאן. Primary endpoints: Maximum tolerated dose and Safety. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
RMC BCMA CAR T-cell therapy
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2024-11-03_013658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-03_013658.